Follow
Mohit Narang
Mohit Narang
US Oncology Research , Maryland Oncology Hematology
Verified email at usoncology.com - Homepage
Title
Cited by
Cited by
Year
Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes
JJ Shah, R Abonour, C Gasparetto, JW Hardin, K Toomey, M Narang, ...
Clinical Lymphoma Myeloma and Leukemia 17 (9), 575-583. e2, 2017
872017
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
H Yimer, J Melear, E Faber, WI Bensinger, JM Burke, M Narang, ...
British journal of haematology 185 (3), 492-502, 2019
612019
Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA® registry
DL Grinblatt, MA Sekeres, RS Komrokji, AS Swern, KA Sullivan, M Narang
Leukemia & lymphoma 56 (4), 887-895, 2015
492015
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
R Abonour, L Wagner, BGM Durie, S Jagannath, M Narang, HR Terebelo, ...
Annals of Hematology 97, 2425-2436, 2018
402018
Recognition of early mortality in multiple myeloma by a prediction matrix
H Terebelo, S Srinivasan, M Narang, R Abonour, C Gasparetto, K Toomey, ...
American journal of hematology 92 (9), 915-923, 2017
392017
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
S Jagannath, R Abonour, BGM Durie, M Narang, HR Terebelo, ...
Blood advances 2 (13), 1608-1615, 2018
322018
Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)
M Narang, JA Penner, D Williams
American journal of hematology 74 (4), 263-267, 2003
322003
Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016)
S Jagannath, R Abonour, BGM Durie, C Gasparetto, JW Hardin, ...
Clinical Lymphoma Myeloma and Leukemia 18 (7), 480-485. e3, 2018
312018
Connect MM®–the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide
RM Rifkin, R Abonour, JJ Shah, J Mehta, M Narang, H Terebelo, ...
Leukemia & Lymphoma 57 (9), 2228-2231, 2016
282016
Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
S Ailawadhi, S Jagannath, HC Lee, M Narang, RM Rifkin, HR Terebelo, ...
Cancer 126 (19), 4332-4340, 2020
212020
Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry
HR Terebelo, R Abonour, CJ Gasparetto, K Toomey, BGM Durie, ...
British Journal of Haematology 187 (5), 602-614, 2019
192019
A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of myelodysplastic syndromes (MDS).
MA Sekeres, JP Maciejewski, DW Donley, DL Grinblatt, M Narang, ...
Blood 114 (22), 3797, 2009
192009
Treatment outcomes and health care resource utilization in patients with newly diagnosed multiple myeloma receiving lenalidomide-only maintenance, any maintenance, or no …
RM Rifkin, S Jagannath, BGM Durie, M Narang, HR Terebelo, ...
Clinical Therapeutics 40 (7), 1193-1202. e1, 2018
182018
Connect MM Registry as a national reference for United States multiple myeloma patients
S Ailawadhi, S Jagannath, M Narang, RM Rifkin, HR Terebelo, K Toomey, ...
Cancer medicine 9 (1), 35-42, 2020
172020
Treatment journeys of patients with newly diagnosed multiple myeloma (NDMM): results from the Connect MM Registry
S Jagannath, RM Rifkin, CJ Gasparetto, K Toomey, BGM Durie, ...
Clinical Lymphoma Myeloma and Leukemia 20 (5), 272-276, 2020
162020
Lyra: a phase 2 study of daratumumab (Dara) plus cyclophosphamide, bortezomib, and dexamethasone (Cybord) in newly diagnosed and relapsed patients (Pts) with multiple myeloma (MM)
H Yimer, J Melear, E Faber, W Bensinger, JM Burke, M Narang, ...
Blood 132, 152, 2018
162018
Effect of t (11; 14) abnormality on outcomes of patients with newly diagnosed multiple myeloma in the connect MM registry
C Gasparetto, S Jagannath, RM Rifkin, BGM Durie, M Narang, ...
Clinical Lymphoma Myeloma and Leukemia 22 (3), 149-157, 2022
152022
Health-related quality of life of patients with newly diagnosed multiple myeloma receiving any or lenalidomide maintenance after autologous stem cell transplant in the Connect …
R Abonour, BGM Durie, S Jagannath, JJ Shah, M Narang, HR Terebelo, ...
Blood 128 (22), 537, 2016
152016
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study
H Yimer, J Melear, E Faber, WI Bensinger, JM Burke, M Narang, ...
Leukemia & lymphoma 63 (10), 2383-2392, 2022
112022
Treatment of Patients with Low-Risk Myelodysplastic Syndromes Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry.
DL Grinblatt, M Narang, JM Malone III, DA Sweet, TS Dunne, KA Sullivan
Blood 112 (11), 1646, 2008
112008
The system can't perform the operation now. Try again later.
Articles 1–20